<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00337116</url>
  </required_header>
  <id_info>
    <org_study_id>sor435006ctil</org_study_id>
    <nct_id>NCT00337116</nct_id>
  </id_info>
  <brief_title>Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients</brief_title>
  <official_title>Intravenous Isosorbide Dinitrate Versus Sublingual Isosorbide Dinitrate for the Relief of Acute Anginal Episodes in Acute Coronary Syndrome (ACS) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Soroka University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Soroka University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double blind, placebo-controlled study, clinical trail designed to&#xD;
      evaluate the efficacy safety and superiority of intravenous boluses of isosorbide dinitrate&#xD;
      for the relief of acute anginal pain episodes in acute coronary syndrome patients in&#xD;
      comparison with the usual manner of S/L isosorbide dinitrate .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Analgesia is an important element in the management of ACS patients. Pain contributes to the&#xD;
      heightened sympathetic activity that is particularly prominent during periods of acute STEMI,&#xD;
      NSTEMI and unstable angina and consequentially causes elevation of tissue oxygen demand.&#xD;
      Control of cardiac pain is typically accomplished with a combination of oxygen, analgesic&#xD;
      (e.g. morphine) beta blockers agents and primarily nitrates.&#xD;
&#xD;
      Sublingual nitrates are currently the guidelines recommended preparation for instant relief&#xD;
      of brief episodes of pain. In patients with prolonged periods of waxing and waning chest&#xD;
      pain, drip of intravenous nitrates may be of benefit in controlling of symptoms and&#xD;
      correcting ischemia.&#xD;
&#xD;
      Intravenous nitrates are also indicated for the treatment of acute decompensated CHF patients&#xD;
      with pulmonary edema, nevertheless the current treatment for these patients edema is repeated&#xD;
      intravenous boluses of and not sublingual isosorbide dinitrate, followed by continuous drip.&#xD;
      Although there is no hard data on intravenous high-dose nitrates for the relief of acute&#xD;
      anginal pain episodes, our clinical impression with this method is excellent.&#xD;
&#xD;
      Intravenous boluses of isosorbide dinitrate in a hospital setting provides immediate,&#xD;
      accurate (bioavailability ) and is an easily controlled modality for providing nitrates.&#xD;
&#xD;
      Since intravenous boluses of isosorbide dinitrate is the standard care for acute anginal pain&#xD;
      episodes in our ICCU at this time, a well designed comparative study for the two methods&#xD;
      would help it to become a guideline and not a matter of choice in these cases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    LOGISTIC DIFFICULTIES&#xD;
  </why_stopped>
  <start_date>January 2007</start_date>
  <completion_date type="Anticipated">January 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Unstable Angina</condition>
  <condition>Myocardial Infarction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iso sorbide dinitrate iv bolus or s/l</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt; 18 years or older.&#xD;
&#xD;
          2. Admission to the ICCU with ACS (non-ST elevation acute coronary syndrome or 24 hours&#xD;
             after ST elevation myocardial infarction) .&#xD;
&#xD;
          3. Presence of ischemic symptoms (≥5 minutes) during hospitalization.&#xD;
&#xD;
          4. Pain assessment of 3 out of 10 on Visual Analog Scale (VAS) 1 or dynamic ECG findings&#xD;
             (ST segment deviation ≥0.05 mV or T wave inversion ≥ 0.3 mV)&#xD;
&#xD;
          5. Willing and able to provide written informed consent according to the regulations of&#xD;
             the Ministry of Health and the Helsinki committee instructions.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient who meet any of the following criteria are excluded from the study:&#xD;
&#xD;
          2. Persistent ST-segment elevation ≥ 1 mV in 2 or more contiguous leads or new LBBB.&#xD;
&#xD;
          3. Acute pulmonary edema&#xD;
&#xD;
          4. Sepsis&#xD;
&#xD;
          5. Sustained systolic blood pressure &lt; 90 mm Hg or evidence of cardiogenic shock&#xD;
&#xD;
          6. Pregnant women&#xD;
&#xD;
          7. Use at randomization of agents known to enhance the efficacy of nitrates.&#xD;
&#xD;
          8. Clinically significant aortic stenosis&#xD;
&#xD;
          9. Cr &gt; 2 mg/dL&#xD;
&#xD;
         10. Participation in another trial of an investigational drug or device on randomization.&#xD;
&#xD;
         11. Allergy or sensitivity to nitatrate compounds&#xD;
&#xD;
         12. Acute episode of cerebrovascular attack&#xD;
&#xD;
         13. Inability to comply with the protocol and follow-up&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>doron zahger, prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>soroka university medical center israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Intensive Cardiac Care Unit</name>
      <address>
        <city>Beer Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>June 14, 2006</study_first_submitted>
  <study_first_submitted_qc>June 14, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2006</study_first_posted>
  <last_update_submitted>January 27, 2010</last_update_submitted>
  <last_update_submitted_qc>January 27, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>DORON ZAHGER</name_title>
    <organization>SOROKA UNIVERSITY MEDICAL CENTER</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Angina, Unstable</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

